Company Overview
| Stock Name | Immuneonco-B |
|---|---|
| Stock Code | 01541 |
| Company Full Name | To be extracted |
| Industry | 醫療保健 |
| Principal Activities | 公司是一家以科研為導向的生物技術公司,致力于開發腫瘤免疫療法。 |
| Listing Date | 2023-09-05 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國上海市浦東新區中國(上海)自由貿易試驗區張衡路1000弄15號樓 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | http://www.immuneonco.com/ |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 18.60 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 72.8% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 31,895,280 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 200 | HK$ 3,720 |
| 2 lots | 400 | HK$ 7,440 |
| 3 lots | 600 | HK$ 11,160 |
| 4 lots | 800 | HK$ 14,880 |
| 5 lots | 1,000 | HK$ 18,600 |
| 6 lots | 1,200 | HK$ 22,320 |
| 7 lots | 1,400 | HK$ 26,040 |
| 8 lots | 1,600 | HK$ 29,760 |
| 9 lots | 1,800 | HK$ 33,480 |
| 10 lots | 2,000 | HK$ 37,200 |
| 15 lots | 3,000 | HK$ 55,800 |
| 20 lots | 4,000 | HK$ 74,400 |
| 25 lots | 5,000 | HK$ 93,000 |
| 30 lots | 6,000 | HK$ 111,600 |
| 35 lots | 7,000 | HK$ 130,200 |
| 40 lots | 8,000 | HK$ 148,800 |
| 45 lots | 9,000 | HK$ 167,400 |
| 50 lots | 10,000 | HK$ 186,000 |
| 75 lots | 15,000 | HK$ 279,000 |
| 100 lots | 20,000 | HK$ 372,000 |
| 125 lots | 25,000 | HK$ 465,000 |
| 150 lots | 30,000 | HK$ 558,000 |
| 175 lots | 35,000 | HK$ 651,000 |
| 200 lots | 40,000 | HK$ 744,000 |
| 225 lots | 45,000 | HK$ 837,000 |
| 250 lots | 50,000 | HK$ 930,000 |
| 300 lots | 60,000 | HK$ 1,116,000 |
| 400 lots | 80,000 | HK$ 1,488,000 |
| 500 lots | 100,000 | HK$ 1,860,000 |
| 750 lots | 150,000 | HK$ 2,790,000 |
| 1,000 lots | 200,000 | HK$ 3,720,000 |
| 1,250 lots | 250,000 | HK$ 4,650,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1,500 lots | 300,000 | HK$ 5,580,000 |
| 1,750 lots | 350,000 | HK$ 6,510,000 |
| 4,287 lots | 857,400 | HK$ 15,947,640 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | None |
|---|---|
| HK Market Cap | --- |
| Est. Threshold | --- |
| Analysis Result | 无法确定入通路径 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
| First Day Close | HK$ 19.52 |
|---|---|
| First Day Open | HK$ 21.2 |
| First Day Change | 4.95% |
| First Day Volume | 894500.0 |
| First Day Turnover | 18659600.0 |
| Use of Proceeds | 1、約40.0%,或93.8百萬港元,將用于我們核心產品IMM01(SIRPα-Fc融合蛋白)正在進行及計劃開展的臨床試驗、籌備注冊申請以及計劃的商業化上市;
2、約28.0%,或65.7百萬港元,將用于我們核心產品IMM0306(CD47×CD20)、IMM2902(CD47×HER2)及IMM2520(CD47×PD-L1)正在進行及計劃開展的臨床試驗、籌備注冊申請以及計劃的商業化上市;
3、約10.0%,或23.5百萬港元,將用于IMM47(CD24單克隆抗體)計劃開展的臨床試驗;
4、約5.0%,或11.7百萬港元,將用于IMM2510(VEGF×PD-L1)及IMM27M(CTLA4ADCC增強型單克隆抗體)正在進行的臨床試驗;
5、約7.0%,或16.4百萬港元,將用于建設我們于上海張江科學城的新生產設施;
6、約5.0%,或11.7百萬港元,將用于我們多個臨床前及發現階段資產的持續臨床前研發以及CMC以支持臨床試驗;
7、約5.0%,或11.7百萬港元,將用于營運資金及一般公司用途。 |
Underwriting Syndicate
Joint Bookrunners (8)
Joint Lead Managers (8)
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Harvest International Premium Value (Secondary Market) Fund SPC | 156,626,880 HKD | — | 49.11% | — | 6 months | 2024-03-05 |
| 2 | WuXi Biologics Healthcare Venture | 39,093,480 HKD | — | 12.26% | — | 6 months | 2024-03-05 |
| 3 | 昆翎医药发展有限公司 | 15,504,960 HKD | — | 4.86% | — | 6 months | 2024-03-05 |
| 4 | 荣昌生物香港有限公司 | 20,999,400 HKD | — | 6.58% | — | 6 months | 2024-03-05 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 田文志 | — |
| Company Secretary | 關梅,李健威 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 田文志(18.80%);禮來亞洲基金(11.70%);上海張科領弋升帆創業投資中心(有限合伙)(11.34%);北京龍磐健康醫療投資中心(有限合伙)(5.16%) |
|---|




